

Megan Neary

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4770226/megan-neary-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

24
papers

281
citations

8
h-index

16
g-index

27
ext. papers

397
ext. citations

5.5
avg, IF

3.2
L-index

#	Paper	IF	Citations
24	Lack of Ronapreve (REGN-CoV; casirivimab and imdevimab) virological efficacy against the SARS-CoV-2 Omicron variant (B.1.1.529) in K18-hACE2 mice. 2022 ,		2
23	Evaluation of intranasal nafamostat or camostat for SARS-CoV-2 chemoprophylaxis in Syrian golden hamsters 2021 ,		1
22	Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2078-2088	3.8	21
21	Development of a highly sensitive bioanalytical assay for the quantification of favipiravir 2021 ,		1
20	Optimisation and validation of a sensitive bioanalytical method for niclosamide 2021 ,		1
19	Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. <i>Nanoscale</i> , 2021 , 13, 6410-6416	7.7	2
18	Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 775-790	6.1	75
17	Do genetic variations in proximal tubule transporters influence tenofovir-induced renal dysfunction? An exploratory study in a Ghanaian population. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1267-1271	5.1	2
16	Genetic influence of ABCG2, UGT1A1 and NR112 on dolutegravir plasma pharmacokinetics. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1259-1266	5.1	2
15	Pharmacokinetics of HIV therapies in pregnant patients: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 449-461	5.5	1
14	Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis 2020 ,		4
13	Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 1670-1678	5.1	22
12	A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz035	1	4
11	Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals. <i>Clinical Infectious Diseases</i> , 2019 , 68, 446-452	11.6	18
10	Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 3281-3290	5.1	8
9	Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 3003-3010	5.1	5
8	Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics. <i>Pharmacogenomics</i> , 2019 , 20, 217-223	2.6	1

7	Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum. <i>Clinical Infectious Diseases</i> , 2018 , 67, 785-790	11.6	19
6	The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 529-536	6.1	20
5	Pharmacogenetic considerations for HIV treatment in different ethnicities: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 1169-1181	5.5	8
4	Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study. <i>Pharmacogenetics and Genomics</i> , 2016 , 26, 381-9	1.9	8
3	The role of drug transporters in the kidney: lessons from tenofovir. <i>Frontiers in Pharmacology</i> , 2014 , 5, 248	5.6	43
2	Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics		11
1	Naturally-acquired immunity in Syrian Golden Hamsters provides protection from re-exposure to emerging heterosubtypic SARS-CoV-2 variants B.1.1.7 and B.1.351		2